TABLE 2.
Baseline characteristics (n=254 treatment-naïve patients with pulmonary arterial hypertension (PAH))
| Age (years) | 55 (42–66) |
| Female | 201 (79) |
| BSA (m2) | 1.80±0.35 |
| PAH subcategory | |
| IPAH | 94 (37) |
| CTD | 105 (41) |
| CHD | 21 (8) |
| Portal hypertension | 16 (6) |
| Other PAH | 18 (7) |
| WHO Functional Class | |
| II | 10 (4) |
| III | 210 (83) |
| IV | 34 (13) |
| REVEAL 2.0 score | |
| ≤6 | 11 (4) |
| 7–8 | 173 (68) |
| ≥9 | 70 (28) |
| 2022 ESC/ERS risk | |
| Low | 18 (7) |
| Intermediate | 169 (66) |
| High | 67 (26) |
| RHC parameters | |
| mPAP (mmHg) | 50 (41–59) |
| PVR (dyn·s·cm−5) | 812 (526–1154) |
| PAWP (mmHg) | 10 (8–12) |
| mRAP (mmHg) | 9 (6–14) |
| CO (L·min−1) | 4 (3–5) |
| SvO2 (%) | 64 (58–70) |
| Heart rate (beats·min−1) | 77 (69–89) |
| PAH medication | |
| PDE5i | |
| Sildenafil | 199 (78) |
| Tadalafil | 20 (8) |
| ERA | |
| Ambrisentan | 87 (34) |
| Bosentan | 33 (13) |
| Macitentan | 62 (24) |
| Parenteral prostanoid | 43 (17) |
| Other | 11 (4) |
| Therapeutic strategy | |
| Monotherapy | 74 (32) |
| Dual combination | 111 (48) |
| Triple combination | 45 (20) |
Data are presented as median (interquartile range), n (%) or mean±sd. BSA: body surface area; IPAH: idiopathic PAH; CHD: congenital heart disease; CTD: connective tissue disease; WHO: World Health Organization; ESC: European Society of Cardiology; ERS: European Respiratory Society; RHC: right heart catheterisation; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; PAWP: pulmonary arterial wedge pressure; mRAP: mean right atrial pressure; CO: cardiac output; SvO2: mixed venous oxygen saturation; PDE5i: phosphodiesterase 5 inhibitor; ERA: endothelin receptor antagonist.